Treatment of Anti-GBM Glomerulonephritis
Initiate treatment immediately with high-dose corticosteroids and plasma exchange as soon as anti-GBM disease is suspected—do not wait for diagnostic confirmation—and add cyclophosphamide once infection is ruled out. 1
Immediate Treatment Protocol
Start Without Delay (Even Before Confirmation)
- Methylprednisolone (pulse dosing) followed by oral prednisone taper over 6 months 1
- Plasma exchange immediately to rapidly remove pathogenic antibodies 1
- Use albumin replacement for standard cases
- Use fresh frozen plasma if alveolar hemorrhage present or recent kidney biopsy performed 1
- Cyclophosphamide can be started empirically after ruling out infection, but ideally after disease confirmation 1
This aggressive approach is critical because anti-GBM disease is rapidly progressive and fatal if untreated, and early treatment directly correlates with renal survival 1.
Standard Immunosuppression Regimen
Cyclophosphamide
Glucocorticoids
Plasma Exchange Duration
- Continue until anti-GBM titers are undetectable on 2 consecutive tests 1
- 97% of cases achieve undetectable antibodies within 8 weeks 1
- Extended plasma exchange should continue as long as renal viability exists 1
Prophylaxis
- Trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis until cyclophosphamide is complete AND prednisone dose is <20 mg daily 1
Critical Decision Point: Who NOT to Treat
Do NOT treat patients who meet ALL of the following criteria:
- Dialysis-dependent at presentation
- 100% crescents on adequate kidney biopsy
- No pulmonary hemorrhage 2
These patients have only 8% renal recovery rate and >90% remain on dialysis at 1 year 1. However, DO treat if any of these features are present despite dialysis dependency:
- Acute, nonoliguric presentation
- Acute tubular injury on biopsy
- <50% glomerulosclerosis
- <100% crescents
- Minimal tubular atrophy/interstitial fibrosis 1
Always treat patients with alveolar hemorrhage regardless of renal status 2.
Maintenance Therapy
Isolated Anti-GBM Disease
No maintenance immunosuppression is necessary 1. The relapse rate is <5% in treated anti-GBM disease, making maintenance therapy unnecessary 1. The disease is monophasic and self-limited 2.
Double-Positive Patients (Anti-GBM + ANCA)
Treat with maintenance therapy as for ANCA-associated vasculitis 1. These patients have relapse rates equivalent to AAV patients, not isolated anti-GBM disease, requiring ongoing maintenance immunosuppression 1.
Refractory Disease
For patients not responding to standard therapy:
- Rituximab or mycophenolate mofetil (MMF) 1
- Consider clinical trial enrollment where available 1
- Emerging therapy: Imlifidase (IgG-degrading enzyme) showed 67% dialysis-free survival at 6 months in phase 2 study when combined with plasma exchange and corticosteroids 1
Kidney Transplantation
Postpone transplantation until anti-GBM antibodies remain undetectable for ≥6 months 1. Recurrence after transplantation is very low in patients without detectable antibodies 1.
Important Prognostic Factors
Kidney biopsy provides critical prognostic information to guide treatment decisions. Key features:
- Degree of acute tubular necrosis
- Percentage of crescents
- Percent of tubular atrophy/interstitial fibrosis 1
Patients with serum creatinine >500 μmol/L (5.7 mg/dL) who do NOT require dialysis within 72 hours still benefit from immunosuppression 1.
Common Pitfalls to Avoid
- Delaying treatment while awaiting confirmation: Start empirical therapy immediately when anti-GBM is suspected 1
- Treating dialysis-dependent patients with 100% crescents and no pulmonary hemorrhage: These patients have minimal chance of renal recovery and face significant treatment toxicity 1
- Stopping plasma exchange too early: Continue until antibodies are negative on 2 consecutive tests 1
- Using maintenance therapy in isolated anti-GBM disease: Unnecessary given <5% relapse rate 1
- Failing to use maintenance therapy in double-positive patients: These patients behave like AAV and require ongoing treatment 1